Objectives: Avascular necrosis (AVN) is associated with significant morbidity potentially causing severe pain and disability; patients with inflammatory bowel disease (IBD) have a higher prevalence of AVN compared with non-IBD populations. The purpose of our study was to determine the prevalence of AVN in our IBD population and to evaluate these subjects for the presence of clinical characteristics associated with AVN on computed tomography (CT) imaging.
A vascular necrosis (AVN) (or osteonecrosis) is a condition of bone destruction through infarction of its cellular components that is most commonly but not exclusively observed in the femoral head. 1 The presumed mechanism is an abrupt loss of blood supply as a result of vascular compromise commonly associated with an underlying disease including a variety of factors including hematologic disorders, hemoglobinopathies, and systemic lupus erythematosus (SLE).
Avascular necrosis has also been associated with high-dose corticosteroid disease management as this intervention is also believed to contribute to bone destruction. 2, 3 It is estimated that AVN develops in 9% to 40% of patients receiving long-term corticosteroid therapy, and this risk appears to be increased with higher doses and prolonged courses. [4] [5] [6] The adverse impact of chronic corticosteroid utilization on bone is multifactorial; there are direct effects on osteoclasts and osteoblasts, and apoptosis of osteoblasts is accompanied by prolongation of the life span of osteoclasts. Further, increased apoptosis of osteocytes also occurs with concomitant decreases of bone strength. 7 Patients with inflammatory bowel disease (IBD) can be exposed to prolonged and/or high doses of corticosteroids, and this relationship has been suggested as the cause of a low but increased incidence of AVN in this patient population. 2 However, as observed with SLE, it has been suggested that IBD itself may also predispose to osteonecrosis with or without concomitant use of corticosteroid therapies. 8 In a systematic review of computed tomography (CT) scans by an experienced, musculoskeletal fellowship-trained radiologist (T.J.L.) that had been previously obtained for gastrointestinal clinical indications in patients with IBD, we observed a cohort of patients with CT evidence of AVN of the hip. This finding enabled us to identify the prevalence of AVN in our IBD study population, as well as to evaluate IBD-related risk factors, steroid exposure, and whether CT reports detected AVN on initial reads. We also observed whether there was a clinical correlation between the radiologic findings and the patient's signs and symptoms. The results of these assessments are reported herein.
METHODS
The MIRIAD (Mucosal Immunology Repository for Inflammatory and Digestive Diseases) biorepository at the IBD Center at Cedars-Sinai Medical Center houses biospecimens from IBD subjects and contains demographic, longitudinal clinical, serological, and genetic data generated from these subjects. Using the database, we identified 3176 patients with IBD and available genomic data (genome-wide association study). 9, 10 Among this cohort, 1313 patients with CT scans of the abdomen and pelvis that were obtained for IBD-related clinical indications were available for rereview by a fellowship-trained musculoskeletal radiologist. From these 1313 subjects, 27 patients were identified as having clear-cut CT findings consistent with AVN. We used standard CT descriptive criteria for AVN; these criteria were applied to axial CT scans, which were also reformatted into coronal and sagittal images. Imaging criteria include loss of normal trabecular pattern in the femoral head, sclerosis of femoral head, crescentic subchondral lucency, geographic lesion of the femoral head with serpentine or crescentic border, and collapse of superior femoral head surface. Some of the cases had confirmation from magnetic resonance imaging, which is a more sensitive modality to evaluate for presence of AVN.
The recruitment of study subjects is described in Figure 1 . In cases where multiple CT scans were available on a single subject, the most recent CT scans were reviewed. This study was approved as exempt by the institutional review board at Cedars-Sinai Medical Center. Historical chart review was performed to obtain demographic and clinical data for this subset of IBD patients with AVN including age, sex, type of IBD, disease duration and extent, data on steroid use, and documentation in the medical records of hip or low-back pain.
Logistic regression was used to examine the association of AVN with serologic markers, IBD clinical phenotypes, and smoking behaviors. Current age and sex were included as covariates to control for potential confounding. p < 0.05 was considered to be statistically significant.
RESULTS

Prevalence of AVN
Twenty-seven of 1313 IBD patients (approximately 2.1%) were found to have CT evidence of AVN (Fig. 1 ). Of these 27 patients, 16 did not have AVN reported on the initial CT read. Within this subgroup of 16, 6 patients had documented complaints of hip or low-back pain, whereas 10 did not. Among the 11 patients with AVN reported on the initial CT read, all had documented symptoms of hip or low-back pain, whereas 7 had undergone treatment of AVN. None of the 16 patients who did not have a report AVN on the initial CT read had undergone treatment of AVN. Table 1 provides demographic characteristics of these 27 patients. Most patients had Crohn disease (CD) (70%) and were male (63%). The mean age at time of diagnosis of IBD among our 
Characteristics of the Study Population
AVN and Steroid Exposure
We defined high steroid exposure as being exposed to 20 mg of prednisone (or equivalent formulation) daily for at least 6 months, as previously described. [12] [13] [14] Although most AVN patients had documentation of prior exposure to some level of steroids (93%), fewer than half had been on high doses of steroids by our definition, and 2 (7%) had no documented steroid exposure at all (Table 2) .
Radiologic Reporting and Symptoms Suggestive of AVN
In our population, only 11 (41%) of the initial radiology reports commented on the presence of AVN. The remaining 59% were identified retrospectively by musculoskeletal radiologist review, with emphasis on use of bone windows. An example of the detection of AVN that is more prominent on bone windows but not on soft tissue windows is demonstrated in Figure 2 . Sixty-three percent of the IBD cases with AVN had documented complaints of low-back pain and/or hip pain in the record. However, because these studies were referred for abdominal pelvic pathology, these symptoms were unlikely to have been communicated with the radiologist. Notably, of those with negative initial CT reports, only 6 (38%) had documented complaints of hip/low-back pain. 
Association Between Demographic, Clinical, and Serological Characteristics and AVN
Logistic regression was performed to assess demographic and clinical parameters associated with AVN in our patients when compared with the 1286 AVN-negative patients confirmed by CT scan. In CD, smokers were more likely to develop AVN than nonsmokers (odds ratio, 2.9; p = 0.03). Using the Montreal classification, we observed no differences between the presence of AVN regarding disease behavior and disease location in either CD or UC. We did observe an association between anti-neutrophil cytoplasmic antibody (ANCA)-positive status and AVN (odds ratio, 3.05; p = 0.007) in all IBD patients. We also performed a multivariate analysis with all the variables with p < 0.05 in univariate analysis included in a joint model. Similar results were observed (data not shown).
CONCLUSIONS
Avascular necrosis is a diagnosis that carries significant morbidity, potentially causing severe pain and debility. It is known that patients with IBD have a higher prevalence of AVN compared with the general population; however, little is known about the risk factors associated with the development of AVN, the true prevalence among patients with IBD, or measures to prevent susceptibility or progression of this disease. 2 We have confirmed that the prevalence of AVN is higher in IBD populations compared with non-IBD patients with AVN found in approximately 1 in 50 IBD subjects in our study. This is consistent with prior literature that demonstrates a prevalence of 0.5% to 4.3% among patients with IBD, compared with the less than 0.1% in populations without immune-mediated diseases or steroid use. 2, 15 Our study has several novel and/or important findings. We found a significant proportion of IBD patients who are asymptomatic from hip or low-back pain having CT evidence of AVN. We found that by re-examining CT images we could detect findings of AVN, suggesting that careful evaluation of bone windows would allow for improved sensitivity and detection of musculoskeletal disease, not necessarily limited to patients with reported hip or low-back pain. Further, and consistent with prior literature, our data suggest there are other factors that contribute to development of AVN beyond steroid exposure in IBD patients. Lastly, by utilizing existing serological and demographic data, we found an association between both ANCA-positive status across IBD and a smoking history in CD and the presence of AVN within our population.
Our study was notable for the finding of patients with CTevidence of AVN despite the lack of documented symptoms of lowback or hip pain. Lack of symptoms from AVN has been assessed in other disease entities including patients with SLE and in patients who have undergone organ transplantation, where significant proportions of these patients have been found to have CT findings of AVN, without symptoms of hip pain. [16] [17] [18] These findings and our results suggest occult disease exists among asymptomatic, high-risk patient populations. This is the first study to our knowledge that examines the prevalence of incidental findings of AVN among patients with IBD. We found that among IBD patients with CT evidence of AVN many had radiologic reports that did not comment on the presence of AVN. One study that reviewed prior CT enterography images of 357 patients with IBD identified 1 patient with undocumented AVN. 19 This study together with our findings suggests that incidental radiologic findings of AVN among IBD patients are likely underreported. This is an area of concern, given the severe debility, morbidity, and pain associated with progression of AVN. This is especially pertinent among patients with IBD, as previous literature on IBD patients with AVN may have higher revision and complication rates following hip arthroplasty compared with non-IBD patients. 20 Early recognition of AVN may allow for early interventions including use of arthroscopic injections, bone grafts, arthroplasty, utilization of stem cells, or surgical interventions to potentially prevent later complications of untreated AVN and to prevent progression of this disease. In addition, knowledge of underlying AVN may affect treatment decisions by gastroenterologists, including decreased use of corticosteroids. Although abdominal CT scans are most often obtained to evaluate for acute abdominal pathology, it may be beneficial to review imaging using bone window settings with a musculoskeletal radiologist in patients with IBD, whether they report symptoms of hip/low-back pain or not.
Consistent with prior literature, the increased prevalence of AVN among patients with IBD is not adequately explained by steroid exposure. 2, [21] [22] [23] Our study suggests that fewer than half of our cohort had documented exposure to high-dose steroids, and 2 subjects had no steroid exposure at all. In addition, it has also been demonstrated that IBD patients are susceptible to osteonecrosis at lower steroid doses than non-IBD patients. 8 A series cohort study by Klingenstein et al 2 in 2005 examined cumulative steroid doses among IBD patients who developed AVN and was unable to establish a threshold level of corticosteroids associated with the development of osteonecrosis, in keeping with our results.
While steroid exposure is unlikely to be the sole etiologic factor, the exact mechanism responsible for AVN associations with IBD is not known. Inherent IBD-associated coagulopathy, small-vessel vasculitis, and immunologic mechanisms (bone formation and modeling may be suppressed by the presence of inflammatory cytokines including interleukin 1 and tumor necrosis factor α) have all been suggested as etiological factors in the development of osteonecrosis in IBD. 2, 21 While the focus of our study did not include evaluation of these factors, our findings of AVN in patients without exposure to high-dose steroids emphasize the need for further research into these mechanisms. Finally, our findings of an association between smoking history in CD and ANCApositive disease and the presence of AVN point to the possibility of disease severity as an etiologic factor; however, our numbers were too small to draw any firm conclusions. Furthermore, both the smoking and ANCA associations also potentially implicate a vasculitis contribution, but additional work in this underresearched phenomenon will be necessary to confirm this. Our study is observational in nature, limited by the case selection and convenient sample of patients studied, and our imaging findings were read and confirmed by only 1 (yet highly skilled and well-published) musculoskeletal radiologist.
In conclusion, our study demonstrated that approximately 1 in 50 IBD subjects may be at risk of AVN and that a significant proportion of findings of AVN are not reported on routine CT scan radiologist reads. The majority of patients with incidental findings of AVN had reported hip/low-back pain to their gastroenterologist, and sharing these symptoms with radiologists-or reviewing imaging with musculoskeletal radiologists-offers an opportunity to detect early AVN. Further investigation is warranted regarding the etiopathogenetic mechanisms predisposing this population to AVN and to determine preventive strategies in patients with IBD to avoid the potentially debilitating and painful outcomes of this complication.
